Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 3 11Phase 1 3Phase EARLY_PHASE1 2Phase 4 2Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 32Bupivacaine 31Vincristine 27Cisplatin 26Propofol 25Methotrexate 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Bevacizumab 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Ropivacaine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × OTHER × darolutamide × Clear all
NCT06627530 2026-02-11

COAction

Brazilian Clinical Research Institute

Phase 4 Active not recruiting
144 enrolled
Genitourinary

Prostatic Neoplasms

NCT06660862 2026-01-08

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

University of Chicago

Phase 4 Not yet recruiting
80 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡